BeOne Medicines (NASDAQ:ONC – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare BeOne Medicines to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Insider & Institutional Ownership
48.5% of BeOne Medicines shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for BeOne Medicines and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeOne Medicines | 0 | 1 | 16 | 1 | 3.00 |
| BeOne Medicines Competitors | 7845 | 13798 | 25819 | 1039 | 2.41 |
BeOne Medicines presently has a consensus price target of $440.56, indicating a potential upside of 6.74%. As a group, “Pharmaceuticals” companies have a potential upside of 24.78%. Given BeOne Medicines’ rivals higher probable upside, analysts plainly believe BeOne Medicines has less favorable growth aspects than its rivals.
Risk and Volatility
BeOne Medicines has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, BeOne Medicines’ rivals have a beta of -0.04, suggesting that their average stock price is 104% less volatile than the S&P 500.
Earnings and Valuation
This table compares BeOne Medicines and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BeOne Medicines | $6.61 billion | $286.93 million | 52.45 |
| BeOne Medicines Competitors | $18.73 billion | $3.24 billion | 558.92 |
BeOne Medicines’ rivals have higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares BeOne Medicines and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
| BeOne Medicines Competitors | -2,398.26% | -203.62% | -15.08% |
Summary
BeOne Medicines beats its rivals on 8 of the 13 factors compared.
BeOne Medicines Company Profile
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
